Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo Pharma's arm...

    Aurobindo Pharma's arm recalls 2 antibiotic injections from US

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-05-14T14:12:07+05:30  |  Updated On 14 May 2018 2:12 PM IST
    Aurobindo Pharmas arm recalls 2 antibiotic injections from US

    Auro Medics Pharma LLC, a US subsidiary of Aurobindo Pharma Ltd,has initiated voluntary recall of two lots each of two injections from the US market following customer complaints about presence of particles in the vial.


    The fresh recall follows a recent withdrawal of over 1.5 million injections by the company due to "Lack of Assurance of Sterility".

    According to a letter issued to the US Food and Drug Administration department, the recall of Ampicillin and Sulbactam for injection, USP, Single-Dose vial, to the hospital has been initiated due to customer complaints of the presence of red particulate matter in the product.

    The recall of Piperacillin and Tazobactam for injection, USP 3.375 g (Piperacillin Sodium equivalent to 3g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP).

    Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level has been found to contain particulate matter, visible only after reconstitution that was confirmed to be glass within the vial.

    "AuroMedics Pharma LLC is notifying its distributors and customers by recall letters and is arranging for replacement etc. of all recalled product."

    "Consumers, distributors retailers that have the product lot which is being recalled should immediately stop using and return to place of purchase, contact their doctor as appropriate," Auromedics said in the letter on both the recalls.

    Ampicillin and Sulbactamand Piperacillin and Tazobactam Injections are used to treat infections of different natures at different situations.

    Auromedics did not mention the quantities of both the products which are being recalled.

    "To date, AuroMedics Pharma LLC has not received reports of any adverse events or identifiable safety concerns attributed to the product consumed from these lots,"the drug maker said.

    All the injections were manufactured by Aurobindo Pharma Limited at its plant in India, for Auro Medics Pharma, to be distributed in the US.
    Ampicillinantibiotic injectionsAuro Medics PharmaAurobindo PharmaLack of Assurance of SterilityLLCpiperacillinSulbactamtazobactamUSUS Food and Drug Administration
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok